169 related articles for article (PubMed ID: 32816470)
21. Targeted DNA methylation in human cells using engineered dCas9-methyltransferases.
Xiong T; Meister GE; Workman RE; Kato NC; Spellberg MJ; Turker F; Timp W; Ostermeier M; Novina CD
Sci Rep; 2017 Jul; 7(1):6732. PubMed ID: 28751638
[TBL] [Abstract][Full Text] [Related]
22. Cell-specific CRISPR-Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins.
Hoffmann MD; Aschenbrenner S; Grosse S; Rapti K; Domenger C; Fakhiri J; Mastel M; Börner K; Eils R; Grimm D; Niopek D
Nucleic Acids Res; 2019 Jul; 47(13):e75. PubMed ID: 30982889
[TBL] [Abstract][Full Text] [Related]
23. GTR 2.0: gRNA-tRNA Array and Cas9-NG Based Genome Disruption and Single-Nucleotide Conversion in
Gong G; Zhang Y; Wang Z; Liu L; Shi S; Siewers V; Yuan Q; Nielsen J; Zhang X; Liu Z
ACS Synth Biol; 2021 Jun; 10(6):1328-1337. PubMed ID: 34015926
[TBL] [Abstract][Full Text] [Related]
24. Sequential Activation of Guide RNAs to Enable Successive CRISPR-Cas9 Activities.
Clarke R; Terry AR; Pennington H; Hasty C; MacDougall MS; Regan M; Merrill BJ
Mol Cell; 2021 Jan; 81(2):226-238.e5. PubMed ID: 33378644
[TBL] [Abstract][Full Text] [Related]
25. Bridge Helix of Cas9 Modulates Target DNA Cleavage and Mismatch Tolerance.
Babu K; Amrani N; Jiang W; Yogesha SD; Nguyen R; Qin PZ; Rajan R
Biochemistry; 2019 Apr; 58(14):1905-1917. PubMed ID: 30916546
[TBL] [Abstract][Full Text] [Related]
26. CRISPR: development of a technology and its applications.
Derry WB
FEBS J; 2021 Jan; 288(2):358-359. PubMed ID: 33300275
[TBL] [Abstract][Full Text] [Related]
27. Engineering of high-precision base editors for site-specific single nucleotide replacement.
Tan J; Zhang F; Karcher D; Bock R
Nat Commun; 2019 Jan; 10(1):439. PubMed ID: 30683865
[TBL] [Abstract][Full Text] [Related]
28. CRISPR technologies and the search for the PAM-free nuclease.
Collias D; Beisel CL
Nat Commun; 2021 Jan; 12(1):555. PubMed ID: 33483498
[TBL] [Abstract][Full Text] [Related]
29. Optimization of genome editing through CRISPR-Cas9 engineering.
Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
[TBL] [Abstract][Full Text] [Related]
30. Type II anti-CRISPR proteins as a new tool for synthetic biology.
Zhang Y; Marchisio MA
RNA Biol; 2021 Aug; 18(8):1085-1098. PubMed ID: 32991234
[TBL] [Abstract][Full Text] [Related]
31. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9.
Yang H; Patel DJ
Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive deletion landscape of CRISPR-Cas9 identifies minimal RNA-guided DNA-binding modules.
Shams A; Higgins SA; Fellmann C; Laughlin TG; Oakes BL; Lew R; Kim S; Lukarska M; Arnold M; Staahl BT; Doudna JA; Savage DF
Nat Commun; 2021 Sep; 12(1):5664. PubMed ID: 34580310
[TBL] [Abstract][Full Text] [Related]
33. Tamoxifen- and Mifepristone-Inducible Versions of CRISPR Effectors, Cas9 and Cpf1.
Dominguez-Monedero A; Davies JA
ACS Synth Biol; 2018 Sep; 7(9):2160-2169. PubMed ID: 30138555
[TBL] [Abstract][Full Text] [Related]
34. CRISPR/Cas Derivatives as Novel Gene Modulating Tools: Possibilities and In Vivo Applications.
Xu X; Hulshoff MS; Tan X; Zeisberg M; Zeisberg EM
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32344896
[TBL] [Abstract][Full Text] [Related]
35. Genome editing in plants by engineered CRISPR-Cas9 recognizing NG PAM.
Endo M; Mikami M; Endo A; Kaya H; Itoh T; Nishimasu H; Nureki O; Toki S
Nat Plants; 2019 Jan; 5(1):14-17. PubMed ID: 30531939
[TBL] [Abstract][Full Text] [Related]
36. The yeast platform engineered for synthetic gRNA-landing pads enables multiple gene integrations by a single gRNA/Cas9 system.
Baek S; Utomo JC; Lee JY; Dalal K; Yoon YJ; Ro DK
Metab Eng; 2021 Mar; 64():111-121. PubMed ID: 33549837
[TBL] [Abstract][Full Text] [Related]
37. Strong and tunable anti-CRISPR/Cas activities in plants.
Calvache C; Vazquez-Vilar M; Selma S; Uranga M; Fernández-Del-Carmen A; Daròs JA; Orzáez D
Plant Biotechnol J; 2022 Feb; 20(2):399-408. PubMed ID: 34632687
[TBL] [Abstract][Full Text] [Related]
38. Defining genome-wide CRISPR-Cas genome-editing nuclease activity with GUIDE-seq.
Malinin NL; Lee G; Lazzarotto CR; Li Y; Zheng Z; Nguyen NT; Liebers M; Topkar VV; Iafrate AJ; Le LP; Aryee MJ; Joung JK; Tsai SQ
Nat Protoc; 2021 Dec; 16(12):5592-5615. PubMed ID: 34773119
[TBL] [Abstract][Full Text] [Related]
39. CRISPR-Cas "Non-Target" Sites Inhibit On-Target Cutting Rates.
Moreb EA; Hutmacher M; Lynch MD
CRISPR J; 2020 Dec; 3(6):550-561. PubMed ID: 33346713
[TBL] [Abstract][Full Text] [Related]
40. CRISPR-Cas Systems in Streptococci.
Gong T; Lu M; Zhou X; Zhang A; Tang B; Chen J; Jing M; Li Y
Curr Issues Mol Biol; 2019; 32():1-38. PubMed ID: 31166168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
